Leveraging a system of multiple research-oriented hospitals and clinical trial centers, we closely collaborate with top domestic PIs to primarily conduct Phase 1-3 drug clinical trials involving both healthy subjects and patients. Our focus is on establishing the largest and most specialized Phase I clinical trial platform for innovative drugs, aiming to seamlessly integrate the Phase I system into early drug development. This approach aims to enhance the efficiency of drug market conversion, reduce development costs, and manage research and development risks.